[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Seung-Jung Park\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":362},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,43,68,92,119,144,170,194,215,236,258,278,301,320,339],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100147099","evaluation-of-the-first-second-and-new-drug-eluting-stents-in-routine-clinical-practice-100147099",false,"NCT01186133","Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice","Evaluation of Effectiveness and Safety of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice","IRIS-DES","Inclusion Criteria:\n\n* coronary disease amenable to percutaneous coronary intervention (PCI)\n* no clinical and lesion limitations\n\nExclusion Criteria:\n\n* patients with a mixture of several DES\n* terminal illness with life expectancy less than 1 year\n* patients with cardiogenic shock","ALL","19 Years",{"count":20,"type":21},50000,"ESTIMATED","OBSERVATIONAL","The objective of this study is to evaluate effectiveness and safety of the new drug-eluting stent (DES), as compared with the first-,second-,third-, and fourth-generation DES, in the \"real world\" daily practice.",[25,26],"Coronary Artery Disease","Percutaneous Transluminal Coronary Angioplasty",[28,29],"coronary disease","drug eluting stent","RECRUITING","2026-06-26",{"date":33,"type":34},"2026-06-30","ACTUAL",{"date":36,"type":4},"2009-01",{"date":38,"type":21},"2030-12",{"name":40,"class":41},"Seung-Jung Park","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100585909","the-decision-cto-extended-10-y-follow-up-100585909","NCT06908499","The DECISION-CTO Extended 10 Y Follow-up","Ten-Year Outcomes of Randomized Comparison of Drug-eluting Stent Implantation Versus Optimal Medical Treatment in Patient With Chronic Total Occlusion: DECISION-CTO Trial","DecisionCTO10Y","Inclusion Criteria:\n\n1. Clinical 1) Patients with angina or silent ischemia and documented ischemia 2) Patients who are eligible for intracoronary stenting 3) Age \\>18 years\n2. Angiographic 1) De novo lesion Chronic Total Occlusion (CTO) 2) Reference vessel size ≥ 2.5 mm by visual estimation 3) At least one CTO lesions located in proximal or mid epicardial coronary artery.\n\n   (If the patient has two CTO lesions, one CTO lesion should be located in proximal or mid epicardial coronary artery)\n3. CTO definition: TIMI (Thrombolysis in Myocardial Infarction) flow 0 or 1 with estimated duration over 3 months\n\n   * The duration of the occlusion was determined by the interval from the last episode of acute coronary syndrome, or\n   * In patients without a history of acute coronary syndrome, from the first episode of effort angina consistent with the location of the occlusion\n\n     1. Angiographically defined total occlusion over 3 months\n     2. If no definite symptom with total occlusion, two experienced operators decide CTO in consideration of angiographical morphology (degree of calcification, bridging collaterals, non-tapered stump, angiographic filling from collaterals)\n\nExclusion Criteria:\n\n1. History of bleeding diathesis or coagulopathy\n2. Pregnant state\n3. Three vessel CTOs\n4. Known hypersensitivity or contra-indication to contrast agent and heparin\n5. ST-elevation acute myocardial infarction requiring primary stenting\n6. Culprit total occlusion presented with acute coronary syndrome suggesting acute or recent occlusion\n7. Characteristics of lesion 1) Left main disease 2) In-stent restenosis 3) Graft vessels 4) Distal epicardial coronary artery CTO lesions 5) Two vessel proximal segment CTOs\n8. Hematological disease (Neutropenia \\\u003C3000\u002Fmm3, Thrombocytopenia \\\u003C100,000\u002Fmm3)\n9. Hepatic dysfunction, liver enzyme (ALT and AST) elevation ≥ 3 times normal\n10. Renal dysfunction, creatinine ≥ 2.0mg\u002FdL\n11. Contraindication to aspirin, clopidogrel or other commercial antiplatelet agent\n12. Left ventricular ejection fraction \\\u003C30%\n13. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.\n14. Non-cardiac co-morbid conditions are present with limited life expectancy or that may result in protocol non-compliance (per site investigator's medical judgment).",{"count":52,"type":21},840,"The goal of this clinical trial is to compare long term efficacy of drug-eluting stent implantation compare to optimal medical treatment in patient with chronic total occlusion in a very long-term follow-up (minimum 10 years) period.",[25],[56,57,58],"Chronic Total Occlusion","Drug-eluting Stent Implantation","Optimal Medical Treatment","2026-06-23",{"date":61,"type":34},"2026-06-24",{"date":63,"type":34},"2026-04-01",{"date":65,"type":21},"2026-12-31",{"name":40,"class":41},19,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":78,"studyType":22,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},"100529743","iris-coroflex-neo-cohort-100529743","NCT06177743","IRIS-Coroflex NEO Cohort","Evaluation of Effectiveness and Safety of Coroflex ISAR NEO Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study","IRIS Coroflex","Inclusion Criteria:\n\n1. Patients ≥ 19 years old\n2. Patients receiving Coroflex ISAR NEO stents.\n3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthics Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Patients with a mixture of other DESs\n2. Terminal illness with life expectancy \\\u003C1 year.\n3. Patients with cardiogenic shock",{"count":77,"type":21},1000,"5 Years","The objective of this study is to evaluate the effectiveness and safety of Coroflex ISAR NEO stents in comparison to other drug-eluting stents (DES) in real-world practice.",[81,25],"Coronary Artery Stenosis",[83],"percutaneous coronary intervention",{"date":85,"type":34},"2026-06-25",{"date":87,"type":34},"2025-01-09",{"date":89,"type":21},"2032-12-31",{"name":40,"class":41},11,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100503025","fractional-flow-reserve-versus-angiography-for-treatment-decision-and-evaluation-of-significant-left-main-coronary-artery-disease-100503025","NCT05829889","Fractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease","A Comparison of Fractional Flow Reserve- Versus Angiography-Guided Percutaneous Coronary Intervention in Patients With Left Main Coronary Artery Disease","FATE-MAIN","Inclusion Criteria:\n\n1. The subject must be ≥20 years of age with angina and\u002For evidence of myocardial ischemia.\n2. Significant de novo LMCA disease, defined as ≥ 50% diameter stenosis by visual estimation with or without concomitant non-left main major epicardial coronary artery disease, amenable to PCI with drug-eluting stent(DES) implantation.\n3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthical Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. left anterior descending coronary artery (LAD) or left circumflex coronary artery (LCx) chronic total occlusion (CTO)\n2. Extremely calcified or tortuous vessels precluding FFR measurement.\n3. The presence of complex coronary disease anatomy or lesion characteristics or other cardiac condition(s) which leads the participating interventional cardiologist to believe that PCI is not suitable (i.e. the subject should be managed with coronary artery bypass graft or medical therapy alone).\n4. Recent ST Elevation Myocardial Infarction(\\\u003C7 days prior to randomization).\n5. Cardiogenic shock and\u002For need for mechanical\u002Fpharmacologic hemodynamic support.\n6. Severe left ventricular dysfunction (ejection fraction \\\u003C30%).\n7. Requirement for other cardiac surgical procedure (e.g., valve replacement or aorta surgery).\n8. Contraindication or inability to take aspirin or P2Y12 inhibitors (clopidogrel, ticagrelor, or clopidogrel).\n9. Prior PCI of the left main trunk.\n10. Prior coronary artery bypass graft surgery.\n11. Subjects requiring or who may require additional surgery (cardiac or noncardiac) within 1 year.\n12. End-stage renal disease requiring renal replacement therapy.\n13. Liver cirrhosis.\n14. Pregnant and\u002For lactating women.\n15. Concurrent medical condition with a limited life expectancy of less than 2 years.\n16. Subjects who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period. However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion;\n\n1\\) Participated in the observational study expected no effect on the safety and\u002For effectiveness evaluation of this trial.\n\n2\\) Screening failed before any interventional factor is involved.\n\n3\\) Participated in academic trials like strategic comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies.","20 Years",{"count":102,"type":21},960,"INTERVENTIONAL",[105],"NA","The primary purpose of the study was to determine whether the 2-year probability of major adverse cardiac events (primary composite outcome) differed significantly between patients who underwent angiography-guided Percutaneous Coronary Intervention(PCI) and those who underwent Fractional Flow Reserve(FFR)-guided PCI in patients with Left Main Coronary Artery disease(LMCA).",[108,25],"Coronary Artery Disease Left Main",[110,111],"Fractional Flow Reserve","Percutaneous Coronary Intervention",{"date":61,"type":34},{"date":114,"type":34},"2024-04-25",{"date":116,"type":21},"2027-12",{"name":40,"class":41},49,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":128,"conditions":129,"keywords":133,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100330918","iris--desyne-x2-in-the-iris-des-registry-100330918","NCT03588481","IRIS- DESyne X2 in the IRIS-DES Registry","Evaluation of Effectiveness and Safety of DESyne X2 in Routine Clinical Practice; A Multicenter, Prospective Observational Study","IRIS DESyne X2","Inclusion Criteria:\n\n* Age 19 and more\n* Intervention with DeSyne X2 drug-eluting coronary stent\n* Agreed with written informed consent form\n\nExclusion Criteria:\n\n* Intervention with DeSyne X2 drug-eluting coronary stent and other drug eluting stent at the same time\n* Life expectancy of 1year and under\n* Cardiac shock",{"count":77,"type":21},"This study evaluates effectiveness and safety of DESyne X2 in Routine Clinical Practice.",[130,131,132],"Coronary Stenosis","Coronary Occlusion","Coronary Disease",[134,135,136],"PCI","DES","real world",{"date":61,"type":34},{"date":139,"type":34},"2018-11-28",{"date":141,"type":21},"2031-12-31",{"name":40,"class":41},6,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":152,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":103,"phases":155,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":162,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":169,"locationsCount":42},"100636746","preventive-invasive-strategy-for-obstructive-coronary-artery-disease-with-vulnerable-plaque-evaluated-by-coronary-computed-tomography-angiography-2-100636746","NCT07569692","PREventive Invasive Strategy for Obstructive Coronary Artery Disease With Vulnerable Plaque Evaluated by CoroNary Computed Tomography Angiography-2","A Comparison of Initial Invasive Strategy and Initial Conservative Strategy for the Treatment of Vulnerable Atherosclerotic Coronary Plaques Identified by Coronary CT Angiography","PREVENT-2","Inclusion Criteria:\n\n1. Patients aged ≥18 years\n2. Patients with suspected coronary artery disease (CAD) (e.g., chest pain syndrome or equivalent symptoms) who are evaluated with coronary computed tomography angiography (CCTA)\n3. Coronary computed tomography angiography (CCTA) showing:\n\n   Plaque with at least moderate stenosis in one or more major epicardial coronary arteries; and\n\n   At least two high-risk plaque (HRP) feature at the site of stenotic lesions, defined as any of the following:\n   * Low-attenuation plaque (LAP) (\\\u003C70 Hounsfield units)\n   * Positive remodeling (PR) (remodeling index \\>1.2)\n   * Napkin-ring sign (NRS)\n   * Spotty calcification (SC) (\\\u003C3 mm in length)\n4. Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Acute coronary syndrome (ACS) requiring urgent or emergent invasive evaluation\n2. Hemodynamically unstable conditions\n3. Significant left main coronary artery disease (≥50% diameter stenosis)\n4. Coronary anatomy unsuitable for either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)\n5. Left ventricular ejection fraction (LVEF) \\\u003C35%\n\n   → Left ventricular ejection fraction \\\u003C35%\n6. New York Heart Association (NYHA) class III or IV heart failure at entry or hospitalization for exacerbation of chronic heart failure within the previous 6 months\n7. Prior coronary artery bypass grafting (CABG)\n8. Severe renal dysfunction (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m²) or end-stage renal disease on dialysis\n9. Contraindication to undergoing coronary computed tomography angiography (CTA) (e.g., allergy to radiographic contrast that cannot be adequately premedicated, any prior anaphylaxis to radiographic contrast, or inability to cooperate with scan acquisition)\n10. Contraindications to or planned discontinuation of dual antiplatelet therapy within 1 year\n11. Life expectancy less than the duration of the trial due to non-cardiovascular comorbidity\n12. Planned cardiac or major noncardiac surgery within the study period\n13. Women who are breastfeeding, pregnant, or planning to become pregnant during the course of the study\n14. Inability to comply with the study protocol\n15. Active participation in another interventional clinical trial involving an unapproved investigational drug or device","18 Years",{"count":154,"type":21},2500,[105],"The PREVENT-2 trial is to determine whether an initial invasive strategy-consisting of early coronary angiography (CAG) with intent for preventive percutaneous coronary intervention (PCI) in addition to optimal medical therapy (OMT)-reduces the incidence of the primary composite outcome of cardiac death, target-vessel myocardial infarction (MI), unplanned urgent revascularization, or hospitalization for unstable or progressive angina at 3 years, compared with an initial conservative strategy of optimal medical therapy (OMT) alone, in patients with high-risk vulnerable plaque identified by coronary computed tomography angiography (CCTA).",[25],[159,160,161],"vulnerable plaque","coronary computed tomography angiography","preventive percutaneous coronary intervention","NOT_YET_RECRUITING","2026-05-06",{"date":165,"type":34},"2026-05-11",{"date":167,"type":21},"2026-07-30",{"date":141,"type":21},{"name":40,"class":41},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":17,"minAge":178,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":193},"100160835","study-of-the-natural-history-of-ffr-guided-percutaneous-coronary-intervention-100160835","NCT01366404","Study of the Natural History of FFR Guided Percutaneous Coronary Intervention","A Multicenter, Prospective Cohort to Evaluate the Natural History of FFR Guided Percutaneous Coronary Intervention","IRIS FFR","Inclusion Criteria:\n\n* Age 35 years and older\n* FFR measurement on one and more coronary artery stenosis\n* Willing and able to provide informed, written consent\n\nExclusion Criteria:\n\n* Stenosis with TIMI\\\u003C3 flow\n* Graft vessel\n* Ejection fraction \\\u003C 30%\n* Angiographic evidence of extreme tortuosity or calcified coronary vessels\n* Suspected coronary spasm even after sufficient nitrate injected\n* Life expectancy \\\u003C2 year\n* Planned cardiac surgery or planned major non cardiac surgery\n* Woman who are breastfeeding, pregnant or planning to become pregnant during the course of the study\n\nImaging study specific exclusion criteria\n\n* visually-estimated angiographic reference segment diameter of \\\u003C2.75mm or \\>4.0mm\n* Inappropriate for IVUS\u002FVH\u002FOCT procedures : inability for imaging wire or catheter to pass through the tight stenosis, severe calcification, angulation","35 Years",{"count":180,"type":21},20000,"About 20,000 patients with FFR (Fractional Flow Reserve) will be enrolled and evaluated for the natural history of coronary lesions at 2 years clinical and imaging follow-up.",[25],[184],"FFR","2026-03-18",{"date":187,"type":34},"2026-03-20",{"date":189,"type":34},"2011-06",{"date":191,"type":21},"2037-04",{"name":40,"class":41},29,{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":152,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":214},"100158924","observational-study-for-left-main-disease-treatment-100158924","NCT01341327","Observational Study for Left Main Disease Treatment","A GLOBAL, MULTICENTER, PROSPECTIVE, REAL WORLD OBSERVATIONAL STUDY FOR LEFT MAIN DISEASE TREATMENT","IRIS-MAIN","Inclusion Criteria:\n\n* Significant unprotected left main stenosis (\\>50% by visual estimation)\n\n  * The LMCA is considered unprotected if there are no patent coronary artery bypass grafts to the left anterior descending artery or the left circumflex artery.\n* No limitation of clinical or lesion characteristics\n* Age \\>18 years\n* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthics Committee of the respective clinical site.\n\nExclusion Criteria:\n\n* Protected left main stenosis",{"count":203,"type":21},10000,"The purpose of this study is to observe clinical courses for long-term in patients with unprotected LMCA disease and to evaluate comparative results of medical treatment, coronary stenting with drug-eluting stents, and CABG for the treatment of an unprotected LMCA stenosis in the \"real world\" daily practice.",[25],[207],"Left Main",{"date":187,"type":34},{"date":210,"type":34},"2007-07",{"date":212,"type":21},"2033-12",{"name":40,"class":41},42,{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":225,"conditions":226,"keywords":227,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":42},"100514700","evaluation-of-effectiveness-and-safety-of-xience-skypoint-stents-in-routine-clinical-practice-100514700","NCT05981911","Evaluation of Effectiveness and Safety of Xience Skypoint Stents in Routine Clinical Practice","a Non-randomized, Prospective, Open-label Registry to Compare the Effectiveness and Safety of XIENCE Skypoint™ Stents Versus Other DESs in Patients With Coronary Artery Disease","IRIS Skypoint","Inclusion Criteria:\n\n1. Patients ≥ 19 years old\n2. Patients receiving Xience-Skypoint™ stents.\n3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthics Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Patients with a mixture of other DESs\n2. Terminal illness with life expectancy \\\u003C1 year\n3. Patients with cardiogenic shock",{"count":224,"type":21},2000,"The objective of this study is to evaluate the effectiveness and safety of XIENCE Skypoint stents in comparison to other drug-eluting stents (DES) in real-world practice.",[25],[29,111],"2025-12-28",{"date":230,"type":34},"2026-01-02",{"date":232,"type":34},"2023-12-14",{"date":234,"type":21},"2026-12",{"name":40,"class":41},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":257},"100318610","evaluation-of-effectiveness-and-safety-of-rotational-atherectomy-in-routine-clinical-practice-100318610","NCT03427996","Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice","Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice; A Multicenter, Prospective Observational Study","IRIS-ROTA","Inclusion Criteria:\n\n* Patients ≥ 19 years old\n* Patients who received rotational atherectomy\n* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthics Committee of the respective clinical site.\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1y",{"count":245,"type":21},500,"This study evaluates the effectiveness and safety rotational atherectomy in routine clinical practice.",[248,130],"Atherosclerosis, Coronary",[250],"rotational atherectomy",{"date":230,"type":34},{"date":253,"type":34},"2018-09-04",{"date":255,"type":21},"2034-12-31",{"name":40,"class":41},8,{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":277,"locationsCount":42},"100317422","asan-medical-center-myocardial-infarction-registry-100317422","NCT03412435","Asan Medical Center Myocardial Infarction Registry","Asan-MI","Inclusion Criteria:\n\n* All consecutive acute myocardial infarction patients diagnosed through coronary angiography",{"count":266,"type":21},5000,"This study evaluates long-term outcome of patients diagnosed as acute myocardial infarction and treated with medication, coronary artery bypass surgery and percutaneous coronary intervention in Asan medical center, Korea.",[269,130],"Myocardial Infarction, Acute",[271,272],"Acute myocardial infarction","Myocardial infarction",{"date":230,"type":34},{"date":275,"type":34},"2018-04-27",{"date":141,"type":21},{"name":40,"class":41},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":287,"conditions":288,"keywords":289,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":5},"100269832","prognosis-of-coronary-stenosis-based-on-intracoronary-imaging-a-multicenter-prospective-observational-study-100269832","NCT02792075","Prognosis of Coronary Stenosis Based on Intracoronary Imaging; A Multicenter, Prospective Observational Study","IRIS imaging","Inclusion Criteria:\n\n* Patients with intracoronary imaging\n* Written consent\n\nExclusion Criteria:\n\n* Severe calcification and\u002For severe tortuosity\n* Lesion with previous bypass graft surgery (CABG)\n* Left ventricular ejection fraction less than 30 %\n* Coronary spasm\n* Life expectancy less than 2 years\n* Pregnancy or breast-feeding",{"count":286,"type":21},4000,"The purpose of this study is to evaluate the prognosis of coronary stenosis based on intracoronary Imaging.",[25],[130,290,291,292,293,294],"Intracoronary Imaging","VH-IVUS","OCT","NIRS","gray scale IVUS",{"date":230,"type":34},{"date":297,"type":34},"2016-07",{"date":299,"type":21},"2030-06",{"name":40,"class":41},{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":311,"conditions":312,"keywords":313,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":319,"locationsCount":42},"100212230","asan-multivessel-registry-100212230","NCT02039752","Asan Multivessel Registry","Asan Medical Center Registry for Multivessel","ASAN MV","Inclusion Criteria:\n\n* Patients with multivessel disease from 1995 in Asan Medical Center\n* Age 19 and more\n\nExclusion Criteria:\n\n* For prospective cohort, not agreeing to participate with written informed consent form",{"count":310,"type":21},25000,"The purpose of this study is to evaluate long-term prognoses of patients with multivessel coronary disease treated medically or surgically or percutaneously in real world practice.",[25],[314],"Multivessel",{"date":230,"type":34},{"date":317,"type":34},"2014-03",{"date":38,"type":21},{"name":40,"class":41},{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":17,"minAge":152,"maxAge":4,"enrollmentInfo":327,"targetDuration":328,"studyType":22,"phases":4,"briefSummary":329,"conditions":330,"keywords":331,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":42},"100193029","prospective-evaluation-of-drug-eluting-stents-in-routine-clinical-practice-asan-pci-registry-100193029","NCT01788592","Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice (ASAN PCI Registry)","Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice","Inclusion Criteria:\n\n* coronary disease amenable to percutaneous coronary intervention (PCI)\n* no clinical and lesion limitations\n\nExclusion Criteria:\n\n* patients with a mixture of several drug eluting stents\n* terminal illness with life expectancy less than 1 year\n* patients with cardiogenic shock",{"count":20,"type":21},"1 Year","The objective of this study is to evaluate effectiveness and safety of drug-eluting stent implantation in the \"real world\" daily practice.",[25],[332,29],"coronary artery disease",{"date":230,"type":34},{"date":335,"type":34},"2003-01",{"date":337,"type":21},"2030-10",{"name":40,"class":41},{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":17,"minAge":100,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":349,"conditions":350,"keywords":352,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":361},"100212146","drug-eluting-balloon-registry-in-routine-clinical-practice-100212146","NCT02038660","Drug-Eluting Balloon Registry in Routine Clinical Practice","Evaluation of Effectiveness and Safety of Drug-Eluting Balloon in Routine Clinical Practice; A Multicenter Prospective Observational Cohort Study","IRIS DEB","Inclusion Criteria:\n\n* After pre dilatation residual stenosis 30% and less and also without vessel dissection interrupted blood flow\n* Age 20 and more\n* Treated with Balloon angioplasty\n* Signed informed consent and agreed to follow protocol\n\nExclusion Criteria:\n\n* Allergy to paclitaxel, antiplatelet\n* History of side effect to heparin, aspirin, thienopyridines\n* History of bleeding tendency, coagulation disorder, blood transfusion reaction",{"count":348,"type":21},1500,"The purpose of this study is to evaluate long-term effectiveness and safety of patients with coronary disease treated with drug eluting balloon in real world practice.",[25,351],"Angioplasty, Balloon",[25,351],"2025-12-21",{"date":355,"type":34},"2025-12-29",{"date":357,"type":34},"2014-01",{"date":359,"type":21},"2027-06",{"name":40,"class":41},9,""]